更新于：2024-11-01

Snyder Robinson Syndrome

Snyder-Robinson综合征

更新于：2024-11-01

基本信息

别名

INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE、MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE、MRXSSR

+ [17]

简介

X-linked intellectual disability, Snyder type is a rare X-linked intellectual disability syndrome characterized by hypotonia, asthenic build with diminished muscle mass, severe generalized psychomotor delay, unsteady gait and moderate to severe intellectual disability, as well as a long, thin, asymmetrical face with prominent lower lip, long fingers and toes and nasal, dysarthric or absent speech. Bone abnormalities (e.g., osteoporosis, kyphoscoliosis, fractures, joint contractures) are also characteristic. Myoclonic, or myoclonic-like, seizures and renal abnormalities have been associated in some patients.

关联

项与 Snyder-Robinson综合征相关的药物

Polysiloxane Gd-Chelates based nanoparticles

基于聚硅氧烷Gd-螯合物的纳米颗粒

靶点-

作用机制

磁共振成像增强剂

在研机构

NH TherAguix SAS初创企业

原研机构

NH TherAguix SAS初创企业

在研适应症

结直肠癌 [+9]

非在研适应症

宫颈癌

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

Spermine prodrug(University of Central Florida)

靶点

SMS

作用机制

SMS modulators

在研机构

University of Central Florida

原研机构

University of Central Florida

在研适应症

Snyder-Robinson综合征

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

项与 Snyder-Robinson综合征相关的临床试验

NCT06433791 / Enrolling by invitation临床1期

Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine As a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)

Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)

开始日期2024-09-09

申办/合作机构

LadeRx LLC

[+1]

NCT06466720 / Not yet recruitingN/AIIT

Measuring and Mapping Cognitive Decline After Brain Radiosurgery: a Pilot Study

Background Stereotactic Radiosurgery (SRS) is a localised radiotherapy treatment for patients with brain metastases or other benign tumours in the brain, like meningiomas. We do not currently know if, or how much, SRS affects brain function. Patients with brain tumours do not get tested routinely for their brain function.
Understanding short- and long-term side-effects is important for SRS. Brain metastases patients have short life expectancies (6-months to 1-year). However, meningioma patients can live 10 years or more. SRS is used to treat both.
We will use the Montreal Cognitive Assessment (MoCA) to test your brain function. We will use quality-of-life questionnaires QLQ-C30 and BN20. These are specific for patients with brain cancer. They include questions about physical and mental wellbeing.
Why is it important This study aims to identify areas in the brain that relate to changes in brain function after SRS. These areas can then have the radiation dose reduced to them in future patients, hoping to minimise side-effects.
Research Question Which regions of the brain contribute to a decline in brain function following SRS.
Study Design This is a single centre observational study with prospective and retrospective collection of data.
This study will look at two groups of patients:
Group1: Patients will complete the MoCA and two quality-of-life questionnaires before your treatment and every 3 months for a year.
Group2: Patients will complete the MoCA and two quality-of-life questionnaires once.
We will use these tests, your MRI scans and your SRS treatment plan to identify areas of the brain that are responsible for any problems with your brain function.
The participants for Group 1 will be recruited from the SRS Clinics, at City Campus, Nottingham University Hospitals NHS Trust.
The participants for Group 2 will be identified through the Mosaiq Oncology Information System.
This pilot study is funded by the Midlands Mental Health and Neurosciences Network.

开始日期2024-06-10

申办/合作机构

The University of Nottingham

[+1]

NCT06457906 / Recruiting临床3期IIT

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in Patients With Small-Cell Lung Cancer: A Prospective, Randomized, Multicenter Phase III Trial (SHARP Trial)

This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.

开始日期2023-09-01

申办/合作机构

中国医学科学院肿瘤医院

100 项与 Snyder-Robinson综合征相关的临床结果

登录后查看更多信息

100 项与 Snyder-Robinson综合征相关的转化医学

登录后查看更多信息

0 项与 Snyder-Robinson综合征相关的专利（医药）

登录后查看更多信息

1,281

项与 Snyder-Robinson综合征相关的文献（医药）

2024-11-01·Fish & Shellfish Immunology

Current vaccination strategy against Piscirickettsia salmonis in Chile based only on the EM-90 genogroup shows incomplete cross-protection for the LF-89 genogroup

Article

作者: Kani, Takahiro ; Correa, Rodolfo ; Coñuecar, Darling ; Peña, Andrea ; Barrientos, Soraya ; Ildefonso, Ricardo ; Rabascall, Carlos ; Rozas-Serri, Marco ; Jaramillo, Victoria

Piscirickettsia salmonis, the primary bacterial disease in Chilean salmon farming, necessitates a constant refinement of control strategies. This study hypothesized that the current vaccination strategy for SRS control in the Chilean Atlantic salmon aquaculture industry, which has been in place since 2017 (ALPHA JECT® 5.1 plus LiVac®), solely relies on vaccines formulated with the EM-90 genogroup of P. salmonis (PS-EM-90), triggering a partial cross-immunity response in fish infected with the LF-89 genogroup (PS-LF-89). Relative Percent Survival (RPS) and cell-mediated immune (CMI) response were evaluated in Atlantic salmon post-smolts vaccinated with the standard vaccination strategy but challenged with both PS-EM-90 and PS-LF-89, in addition to other vaccination strategies considering primo vaccination and booster with other commercial vaccines and the possible enhancing effects of the combination with a natural immunomodulator (PAQ-Xtract®) administered orally. The intraperitoneal (I.P.) challenge was performed after 2395°-days (DD) after the start of the immunostimulant delivery, 1905 DD after the primo vaccination, and 1455 DD after the booster vaccination. Unvaccinated fish showed 73.6 and 41.7 % mortality when challenged with PS-EM-90 and PS-LF-89, respectively. Fish infected with PS-LF-89 died significantly faster (21 days post-infection, dpi) than fish challenged with PS-EM-90 (28 dpi) (p = 0.0043) and had a higher probability of death (0.4626) than fish challenged with PS-EM-90. RPS had a significant positive correlation with the PS-EM-90 load of the P. salmonis genogroup (r = 0.540, p < 0.01) but not with the PS-LF-89 load (r = 0.155, p > 0.05). This demonstrated that the immunization strategies were more effective in lowering PS-EM-90 loads, resulting in higher survival rates in fish challenged with PS-EM-90. The current industry vaccination strategy recorded a 100 % RPS when fish were challenged with PS-EM-90, but the RPS dropped significantly to 77 % when fish were challenged with PS-LF-89, meaning that the strategy did not show complete cross-protection. But after adding PAQ-Xtract®, the RPS improved from 77 % to 92 % in fish that were vaccinated with the standard method but then challenged with PS-LF-89. The most effective vaccination strategy was based on LiVac® as primo vaccination and ALPHA JECT® 5.1 plus LiVac® as booster vaccination, with or without PAQ-Xtract®, in both PS-EM-90 (100 %) and PS-LF-89 (96 %) challenged fish. The serum concentration of anti-P. salmonis IgM did not show a correlation with the protection of immunization strategies expressed in survival. Low serum IL-12 and high serum IFNγ concentrations showed a correlation with higher bacterial loads and lower survival. Aggregate analysis showed a significant correlation between higher numbers of CD8⁺ cells in the head-kidney, higher fish survival, and a lower bacterial load. The immunization strategies were safe for fish and induced only mild microscopic lesions in the gut. Taken together, our results help to better understand the biological interaction between P. salmonis and post-smolt vaccinated Atlantic salmon to deepen the knowledge on vaccine-induced protection, CMI immune response, and cross-immunity applied to improve the current immunization strategy for SRS control in the Chilean salmon industry.

2024-11-01·Pediatric Blood & Cancer

Documentation of critical intraoperative oncologic findings: Synoptic versus narrative operative reports for childhood cancer surgery

Article

作者: Talbot, Lindsey J. ; Morrison, Zachary ; Abdelhafeez, Abdelhafeez H. ; Davidoff, Andrew M. ; Hosfield, Brian ; Halepota, Huma F. ; Murphy, Andrew J.

AbstractBackgroundDocumentation of intraoperative oncologic findings varies greatly across narrative operative reports (NRs). An international panel of childhood cancer experts recently developed a synoptic operative report (SR) for childhood cancer surgeries. The aim of this study was to compare the documentation of critical intraoperative findings in NRs versus SRs.MethodsA single‐center retrospective review of all surgical resections of primary solid tumors at our pediatric oncology center was conducted from June 2023 to March 2024, after an institutional SR was piloted from October 2023 onwards. Data collected included the presence or absence of six components included in standard pediatric oncology NRs. Inclusion rates were calculated as percentages for each component. Due to the small sample, the Fisher's exact test was used for all hypothesis testing.ResultsSeventy primary tumor resections were performed during the study period, as documented by 38 NRs and 32 SRs. All operative reports after October 2023 were SRs. Completeness of tumor resection and specimen naming were consistently documented in NRs (86% and 100%, respectively) and SRs (100% and 100%, respectively). The presence/absence of three components—intraoperative tumor spillage (31%), vascular involvement (31%), and lymph node sampling (26%)—were documented in fewer than a third of the NRs. Documentation of the presence/absence of locoregional spread, intraoperative tumor spillage, vascular involvement, and lymph node sampling was significantly better in SRs than in NRs.ConclusionAdoption of SRs significantly improved the documentation of critical intraoperative findings. Thus, we recommend using SRs in pediatric solid tumor surgery.

2024-10-01·Quantitative Imaging in Medicine and Surgery

Evaluation of the presence and severity of spontaneous splenorenal or gastrorenal shunts via four-dimensional flow magnetic resonance imaging: a preliminary study

Article

作者: Hu, Qiong ; Zhou, Jun ; Li, Xin ; Guo, Dajing ; Chen, Tianwu ; Zheng, You ; Liu, Xi ; He, Xiaojing ; Chen, Weijuan ; Li, Xiang

BackgroundFour-dimensional phase-contrast magnetic resonance imaging (4D flow MRI) is a relatively new type of MRI acquisition technique that provides a unique and comprehensive set of information within a single acquisition, including hemodynamic and anatomical information. This study was designed to noninvasively evaluate the correlation between the presence and severity of spontaneous splenorenal shunt (SRS) or gastrorenal shunt (GRS) and 4D flow MRI-derived parameters.MethodsThis retrospective case-control study enrolled 70 patients who were diagnosed with hepatocirrhosis portal hypertension and admitted to the Second Affiliated Hospital of Chongqing Medical University. Patients were divided into three groups according to the diameter of the SRS and GRS. 4D flow MRI-derived parameters, including the turbulent kinetic energy, total volume (TV), flow velocity, blood flow volume (BFV), maximum flow (MF), wall shear stress, and relative pressure, were obtained for eight cut planes: proximal to the splenomesenteric confluence and liver hilum of the portal vein (PV₁/PV₂); the left/right branch of the bifurcation of the PV (LPV/RPV), at the mesosplenic confluence of the splenic vein (SV₁), at the splenic hilum of the SV (SV₂); at the proximal to the splenomesenteric confluence of the superior mesenteric vein (SMV₁), and 5 cm from the splenomesenteric confluence of the SMV (SMV₂). Comparisons among the three groups were based on one-way analysis of variance (ANOVA). Logistic regression was used to identify the risk factors for small SRS/GRS (S-SRS/GRS) and for large SRS/GRS (L-SRS/GRS). Receiver operating characteristic curves were used to evaluate the diagnostic performance of the independent risk factors for SRS and GRS. The associations between the clinical data and the 4D flow MRI-derived parameters of GRS and SRS were assessed via Spearman correlation coefficient analysis.ResultsThe presence of SRS or GRS was correlated with TV_LPV (r=-0.302; P=0.035), TV_PV1 (r=-0.385; P=0.001), TV_PV2 (r=-0.301; P=0.013), BFV_PV1 (r=-0.360; P=0.010), BFV_SMV2 (r=0.371; P=0.008), MF_PV1 (r=-0.341; P=0.004), and MF_PV2 (r=-0.291; P=0.017). Meanwhile, the severity of the SRS or GRS was correlated with alanine aminotransferase level (r=-0.535; P<0.001), BFV_LPV (r=-0.560; P=0.008), aspartate aminotransferase level (r=-0.321; P=0.038), and model for end-stage liver disease score (r=0.323; P=0.039). TV_PV1, TV_PV2, BFV_PV1, BFV_PV2, and MF_SMV2 were found to be independent risk factors for L-SRS/GRS, with intermediate diagnostic efficacy, with the area under the curve (AUC)_{TV PV1}=0.706 [95% confidence interval (CI): 0.519-0.853; sensitivity, 61.54%; specificity, 80.77%; P=0.018], AUC_{BFV PV1} =0.694 (95% CI: 0.507-0.844; sensitivity, 95.00%; specificity, 63.16%; P=0.035), AUC_{TV PV2} =0.729 (95% CI: 0.544-0.870; sensitivity, 77.78%; specificity, 66.67%; P=0.016), AUC_{BFV PV2} =0.718 (95% CI: 0.531-0.862; sensitivity, 60.00%; specificity, 82.35%; P=0.017), and AUC_{MF SMV2} =0.788 (95% CI: 0.608-0.912; sensitivity, 44.00%; specificity, 84.46%; P=0.005), respectively. As the TV of PV1 and PV2 and the BFV of PV1 and PV2 decreased, the risk of L-SRS/GRS increased. As the MF of SMV2 increased, the risk of the presence of L-SRS/GRS increased.Conclusions4D flow MRI-derived parameters correlated with the presence and severity of SRS or GRS. Meanwhile, the independent risk factors for the presence of L-SRS/GRS were the TV of LPV, PV1, and PV2; the BFV of PV1 and SMV2; and the MF of PV1 and PV2.

项与 Snyder-Robinson综合征相关的新闻（医药）

2024-10-06

·CPHI制药在线

抗癌“黑科技”电场疗法，显著增加非小细胞肺癌脑转移总生存期，有望2024年上市！

关注并星标CPHI制药在线在过往的数年中，一种崭新的癌症治疗方式——肿瘤治疗电场（Tumor Treating Fields，简称为TTF）慢慢被公众所知晓。肿瘤电场治疗属于一种凭借特定频率的交变电场来阻碍癌细胞分裂，进而遏制癌细胞生长或是转移的医治手段。其是通过在患者的皮肤表层安放特制的绝缘电极贴片，形成低强度的交变电场，穿透皮肤以及身体组织，径直作用于肿瘤所在部位。作为一种非侵入式的物理治疗方法，肿瘤电场治疗主要用于应对部分种类的脑癌与肺癌，吸引了众多患者及其家属的目光。不过，针对这种新兴的疗法，更多的人心中充满疑惑：这究竟是一种科学的医治途径，亦或是又一个顶着高科技名头的骗局？着眼于全球范围，肺癌依旧是在导致死亡的癌症中位居榜首，即便靶向、免疫治疗取得了显著的成果，但此类治疗方式具有一定的毒性，肺癌患者的耐受能力和依从性都遭遇极大考验！研究人员始终在探索全新的治疗模式，以使患者尽可能地规避药物带来的副作用、放疗造成的并发症，在获取更优治疗成效的同时确保高品质的生活。 2024年6月4日，于美国临床肿瘤学会（ASCO）年会上公布的METIS III期临床研究结果表明，电场治疗（TTFields）跟最佳支持治疗（BSC）相结合，对于肺癌脑转移患者有着显著疗效，在添加电场治疗后，肺癌患者的平均脑转移进展时间由 11.3个月延长至21.9个月，进展风险降低 33%。一、肿瘤电场治疗到底是不是智商税？电场主要借助两种机制来抵御癌细胞。其一，因为癌细胞在增殖期间拥有特殊的几何排布形态，并且涵盖带电的细胞成分。所以，施加的电场能够让这些带电细胞变得紊乱，使其“不知所措”，从而损害其正常机能，并最终致使细胞凋亡。另外，癌细胞内包含一些类似“马达”的微型结构件，能够助力癌细胞实现转移和扩散，而肿瘤电场疗法能够对这些“马达”加以干扰和抑制，令它们无法正常运转。在癌细胞分裂的中期，电场作用于微管蛋白的聚合过程，阻挡纺锤体的形成，使得染色体不能正常分离；在癌细胞分裂的末期，电场把电荷推向分裂细胞的颈部，破坏癌细胞的结构。正是由于这两种机制发挥了作用，处于治疗电场中的肿瘤细胞的分裂速度被减缓，甚至死亡，由此抑制癌细胞的转移和扩散，而正常细胞在特定频率的交变电场里，所受到的影响比癌细胞小众多，副作用极小。更为关键的是，这种治疗手段并非仅仅针对局部的肿瘤病灶，而是全方位清理掉体内存在的癌细胞，将敌人尽数剿灭。站在细胞生物学的视角，早在 20 世纪60 年代，科研人员就觉察到电场能够左右细胞的举动。2004 年，以色列科学家 Yoram Palti教授以及其团队率先提出利用交变电场干扰癌细胞分裂这一构想。这些新发现为肿瘤电场治疗技术筑牢了坚实的理论根基。此外，众多的体外实验探究也证实了肿瘤电场治疗对癌细胞的遏制效果。譬如，2007 年发布于《PNAS》（美国国家科学院院刊）的研究表明，肿瘤电场治疗能够明显抑制多种癌细胞的增殖；2010年的一项研究发现，肿瘤电场治疗能够增进化疗药物的治疗成效，呈现出协同作用。2018 年《Scientific Reports》（科学报告）上的一项研究指出，肿瘤电场治疗能够强化放疗对非小细胞肺癌细胞的杀伤效力。在动物模型中，肿瘤电场治疗同样展现出了出色的抗肿瘤功效：2007年的研究表明，肿瘤治疗电场能够极大限度地抑制小鼠皮下移植的人类肺癌肿瘤的生长。2014年发表在《Clinical Cancer Research》（临床肿瘤研究）上的研究发现，肿瘤电场治疗联合化疗可以显著延长携带肺癌脑转移的大鼠的生存期。二、振奋人心的METIS III期临床研究结果 METIS [NCT02831959]属于一项针对立体定向放射外科治疗联合或者不联合 TTFields疗法展开的3 期研究，主要面向患有 1 -10处脑转移病灶的非小细胞肺癌患者。总计298名成年患者参与到了本项研究当中，在进行 SRS之后，随机接受 TTFields疗法与支持治疗的联合，或者仅仅接受支持治疗。这里的支持治疗涵盖了诸如类固醇、抗癫痫药物、抗凝血剂、疼痛控制或者恶心控制等一系列的药物治疗。依照治疗医生的判断，该研究当中的两组患者均具备接受非小细胞肺癌全身性治疗的资格。存在已知肿瘤突变且能使用靶向药物进行治疗的患者并未纳入到此次研究范围。 METIS研究的核心终点为首次颅内进展所历经的时间，从首次SRS 治疗的当日起，一直到出现颅内进展或者神经性死亡（依照 RANO-BM 标准），以率先发生的情况来看。通过累积发生函数来算出颅内进展的时间。患者的扫描结果由独立且盲法的放射学审查委员会进行评定。次要终点包含但不限于至远处进展的时长、至神经认知衰竭的时间、总生存期、至第二次颅内进展的时间、生活质量以及不良事件。倘若成功，关键的次要终点（至神经认知衰竭时间、总生存期以及影像学缓解率）计划在标签声明里得以运用。有关次要终点的全面分析目前仍在进行。依据脑转移的病灶数量（1 -4 处或者 5 -10处转移）、过往全身治疗情况以及肿瘤组织学来对患者予以分层。在确定了第二次颅内进展之后，允许患者交叉到实验组接受TTFields 治疗。 METIS 研究入组了 298 名存在1-10 处 NSCLC 脑转移的成年患者，他们在接受立体定向放射外科 (SRS) 治疗后随机分配接受 TTFields 疗法和最佳支持疗法 (BSC) (n=149) 或单独接受 BSC (n=149)。METIS研究达到了其主要终点，表明延长至颅内进展时间有统计学上显著改善。接受 TTFields 疗法和 BSC 疗法的患者中位至颅内进展时间为 21.9 个月，单独接受 BSC 疗法的患者为 11.3 个月（风险比=0.67；P=0.016）。接受TTFields 疗法的中位持续时间为 16 周，中位使用率为 67%。各组患者之间的人口统计学基线和特征非常平衡。接受 TTFields 疗法的患者无恶化生存期有所改善，TTFields 疗法组的无恶化生存期中位时间未达到，对照组为 7.7 个月（P=0.038）。在 EORTC QLQ C30 和 BN20 患者问卷的大部分量表和项目评估中，接受 TTFields 治疗的患者呈积极趋势。某些生活质量参数具有统计学意义，包括整体健康状况（P=0.036）、身体机能（P=0.037）和疲劳（P=0.032）。TTFields 疗法组的患者报告中认知功能没有恶化。与之前的临床研究一致，TTFields 疗法耐受性良好，没有附加全身毒性。关键次要终点的初步分析未显示统计学意义。随机接受 TTFields 疗法联合BSC疗法的患者的中位总生存期为 11.3 个月，单独接受 BSC 疗法的患者中位总生存期为 10.6 个月。在长达 12 个月的时间内观察到有利于使用 TTFields 疗法的生存趋势，但这种趋势并未持续超过一年。对次要终点的全面分析正在进行中。这些数据已由 Mehta 博士于 2024 年 6 月 3 日星期一上午 10:24（美国中部夏令时间）在 ASCO 中枢神经系统肿瘤会议期间的口头报告（摘要编号 2008）中介绍。Novocure 计划将这些研究结果发表在同行审阅的科学期刊上，并提交给监管机构。三、理性看待肿瘤电场治疗：优势与局限并存和传统的手术以及放疗作对比，肿瘤电场治疗属于非侵入式的，故而不会给人体带来创伤。再者，对比化疗而言，肿瘤电场治疗产生的全身性毒副作用显著更少。最为常见的不良状况为电极贴片所在处的皮肤受到刺激，不过通常来讲程度并不严重。与此同时，在运用肿瘤电场治疗以后，患者能够在平日生活里持续展开治疗，无需频繁地前往医院。尤为重要的是，研究显示，肿瘤电场治疗能够增强化疗和放疗的成效，这给联合治疗的策略给予了新的抉择和思考方向。然而这种治疗手段也有着一定的局限和争议。 1.使用存在困难：一般情况下，患者每天需要花费较长时间（至少18小时）佩戴肿瘤电场治疗的相关设备，这或许会在不同程度上对患者的日常生活形成影响。 2.效果有个体差别：并非所有患者都能够通过肿瘤电场治疗获取到明显的临床获益。 3.费用偏高：当下肿瘤电场治疗的总体费用高昂，这致使一部分患者对这种技术望而却步。比如说，在美国，一款用于治疗胶质母细胞瘤的肿瘤电场治疗系统的费用，在没有商业保险的时候，居然达到了21000 美元/月。肿瘤电场治疗的成效毫无疑问是令人欣喜的，但这并非意味着该项技术没有任何缺陷。就目前而言，肿瘤电场治疗作为一项新兴的技术，在具备众多优点的同时，也存在一些争议和挑战。在 2020 年，中国食品药品监督管理局（NMPA）已经准许了肿瘤电场治疗设备用于新发和复发胶质母细胞瘤的上市申请。尽管国内还未批准此设备用于肺癌，但是相关的临床试验正在热烈开展当中，相信在不远的将来，肺癌患者同样能够从中受益。四、结语身为患者及家属，需理性对待此项新兴技术。当下而言，要是存在契机，能够在主治医生的引领下，思索加入肿瘤电场治疗的肺癌临床试验，这不单会使自身获益，也会给医学事业的发展贡献一份力量。另外，有关肿瘤电场治疗肺癌的研究始终在持续开展，众人能够一直留意这些研究的最新动态，为未来可能存在的使用机遇奠定一定的基石。我们有理由相信，在不久之后，肿瘤电场治疗在肺癌治疗范畴必能大放光芒，获取更为令人欣喜的突破，给更多的肺癌患者送去健康佳音。参考资料： 1.曹奕强等. "肿瘤治疗电场治疗胶质母细胞瘤的研究进展." 中华脑科疾病与康复杂志(电子版) 10.04(2020):234-238. 2.许彦龙等. "肿瘤电场治疗在胶质母细胞瘤治疗中的应用进展." 中国医学物理学杂志 2021年38卷5期, 647-649页, ISTIC CSCD (2021). 3.Giladi, Moshe, et al. "Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo." Seminars in oncology. Vol. 41. WB Saunders, 2014. 4.Davies, Angela M., Uri Weinberg, and Yoram Palti. "Tumor treating fields: a new frontier in cancer therapy." Annals of the New York Academy of Sciences 1291.1 (2013): 86-95. 5.Benson, Laura. "Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors." Seminars in oncology nursing. Vol. 34. No. 2. WB Saunders, 2018. 6.Mun, Elijah J., et al. "Tumor-treating fields: a fourth modality in cancer treatment." Clinical Cancer Research 24.2 (2018): 266-275. 7.Hong, Pengjie, et al. "Tumor treating fields: a comprehensive overview of the underlying molecular mechanism."?Expert review of molecular diagnostics?22.1 (2022): 19-28. 8.Branter,Joshua,SurajitBasu, andStuartSmith. "Tumour treating fieldsinacombinational therapeuticapproach."?Oncotarget 9.93(2018):36631. 9.Zhu, Ping, and Jay-Jiguang Zhu. "Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives." Chinese clinical oncology?6.4 (2017): 41-41. 10.Kirson, Eilon D et al. “Disruption of cancer cell replication by alternating electric fields.”Cancer research?vol. 64,9 (2004): 3288-95. 11.Kirson, Eilon D., et al. "Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors." Proceedings of the National Academy of Sciences?104.24 (2007): 10152-10157. 12.Schneiderman, Rosa S., et al. "TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters." BMC cancer 10 (2010): 1-7. 13.Chung,Hea-Jong, et al. "Transferrinasathermosensitizer inradiofrequencyhyperthermiaforcancertreatment." Scientific reports?8.1 (2018): 13505. 14.Karanam,NarasimhaKumar, et al. "Tumor-treating fieldselicitaconditional vulnerabilityto ionizingradiationviathe downregulationofBRCA1 signaling and reduced DNA double-strand break repaircapacity in non-smallcell lung cancercell lines."?Cell death & disease?8.3 (2017): e2711-e2711. 15.Leal, Ticiana, et al. "Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study." The Lancet Oncology?24.9 (2023): 1002-1017. 16.Ceresoli, Giovanni, et al. "Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial." International Journal of Radiation Oncology, Biology, Physics 104.1 (2019): 230-231. 17.Jia, Yijun, et al. "Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice."?Lung Cancer 137 (2019): 85-93. 18.Mikic, N., et al. "Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial." BMC cancer 21 (2021): 1-8. 19.https://www.bioworld.com/articles/455779-novocure-merck-to-start-combo-trial-of-keytruda-with-tumor-treating-fields-in-first-line-nsclc?v=preview END 来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

ASCO会议临床3期临床结果

2023-04-18

·BioSpace

Monteris Medical Announces Publication of Largest Series of NeuroBlate Laser Interstitial Thermal Therapy for Biopsy-Proven Radiation Necrosis

LITT allows for the prompt cessation of steroids and alleviates symptom burden in brain metastasis patients with radiation necrosis as supported by evidence from 90 patients treated with NeuroBlate laser ablation MINNETONKA, Minn. , April 18, 2023 /PRNewswire/ -- Monteris Medical announced today that a new publication on laser interstitial thermal therapy (LITT) using the NeuroBlate® System to treat patients with radiation necrosis (RN) has been published in the journal, Neuro-Oncology Advances. The largest prospectively-gathered dataset, collected through the company's LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) multi-center study and comprised of 90 patients with biopsy-proven RN, showed that LITT with NeuroBlate is a safe and highly effective minimally invasive option for the treatment of RN. The evidence also demonstrated that following the NeuroBlate procedure, patients tapered corticosteroid use rapidly, showed excellent symptom control and continued systemic cancer treatments, allowing for maximal survival benefit. The evidence gathered from this large cohort of pure RN continues to support the utilization of NeuroBlate LITT for the treatment of RN, an inflammatory process that can occur following stereotactic radiosurgery (SRS). These data showed that patients rapidly discontinued steroid use post-LITT (median time of 13 days), an important benefit, given steroid use may worsen survival rates, particularly for those on immunotherapy. Patients in the study who were undergoing chemotherapy and/or immunotherapy experienced little to no interruption in their treatments post-LITT. This is in contrast to craniotomy, which generally requires that patients pause systemic treatments to facilitate wound healing and recovery time. "LITT compares favorably to historical efficacy of craniotomy and resection yet has a degree of versatility when faced with deeper lesions or with those close to eloquent brain," said Dr. Michael D. Chan, lead author and professor of radiation oncology at Atrium Health Wake Forest Baptist in Winston-Salem, NC. "Compared to historical expectations with craniotomy, LITT has demonstrated favorable hospitalization times and favorable risk profile. It seems that LITT has truly carved itself a role in the management of post-SRS radiation necrosis alongside other tools including steroids, bevacizumab and open resection. I look forward to results of the ongoing prospective studies meant to validate the present findings." The use of stereotactic radiosurgery (SRS) has significantly expanded in recent years as brain metastases have become more common. This is due in part to advances in systemic therapy that enable the long-term control of extracranial disease. The growing use of radiotherapy has also resulted in the proliferation of post-SRS imaging changes, which may represent either RN or tumor growth, a diagnostic question best confirmed via biopsy. Laser interstitial thermal therapy with biopsy offers patients an immediate diagnostic confirmation of the disease process and is a highly effective treatment for RN with respect to local control and symptom management. "We are grateful to our investigators for their continued work to generate clinical proof that supports NeuroBlate as a surgical tool for early intervention for those patients with progressive brain metastases," said Martin J. Emerson, president and chief executive officer of Monteris. "As the leader in the LITT space, Monteris remains uniquely committed to delivering high quality evidence that physicians need when making critical patient care decisions. With more than 1,100 patients enrolled, our prospective LAANTERN study continues to demonstrate a distinct position for NeuroBlate as an evidenced-based, mainstay technology for brain tumors, radiation necrosis, and drug-resistant epilepsy." About LAANTERN LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System) is a post-market study designed to evaluate the performance and utilization of the NeuroBlate® System in the standard of care, "real-world" setting. This is the first prospective multicenter laser ablation study. All sites operate under an IRB-approved protocol and undergo rigorous data management and monitoring practices to ensure data quality and consistency. The registry will follow up to 3,000 patients for five years evaluating safety, quality of life, health economics and procedural outcomes, including survival and seizure freedom. About Monteris and the NeuroBlate System Monteris Medical is a privately held company that develops and markets innovative MR-guided ablation systems to perform minimally invasive, robotically controlled brain surgery, commonly referred to as laser ablation, LITT (Laser Interstitial Thermal Therapy) or SLA (Stereotactic Laser Ablation). The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy. The Monteris Medical NeuroBlate System is a neurosurgical tool and is intended for ablating intracranial soft tissue, including brain structures such as brain tumors, radiation necrosis, and epileptic foci (as identified by non-invasive and invasive neurodiagnostic testing, including imaging). For more information, visit monteris.com.

放射疗法免疫疗法